Support Article
Accuracy and Evidence Behind BAT Testing
BAT Testing measures the balance of Beta-Amyloid (Aβ) and Tau (T), two biomarkers with a large research history across neuroscience and brain-aging literature. The BAT Testing framework uses these biomarkers in plasma form to support structured, repeatable trend tracking over time.
This page summarizes the main evidence and analytical themes behind the BAT Testing model.
Scientific Basis
In the BAT framework, Beta-Amyloid and Tau are used as complementary biological signals:
- Beta-Amyloid (Aβ) is used as a clearance-efficiency marker.
- Tau (T) is used as a marker tied to neuronal stress and structural response.
BAT Testing quantifies this balance through two core laboratory measures: the Aβ42/40 ratio and phosphorylated Tau (typically pTau181 or pTau217). These measurements support BAT Levels and BATScore trend interpretation.
Analytical Accuracy and Lab Standards
BAT Testing is described as an independent laboratory process through CLIA-certified sites under a standardized protocol intended to support cross-site reproducibility.
Inter-assay precision: ≥99% reproducibility between runs and reagent lots
Intra-assay precision: ≤3% within-batch variance
Cross-lab calibration: quarterly reference alignment
Sample stability: 48-72 hours post-collection under validated conditions
Normalization: universal BATScore scaling for cross-site comparability
These targets are used to support consistency when results are compared across locations and over time.
Evidence-Guided Framework
The BAT Testing model describes an internal evidence framework that reviews published work across biomarker validation, assay reproducibility, and longitudinal outcome correlation. Key review areas include:
- validation of plasma Aβ and Tau markers
- correlation with imaging/PET outcomes
- longitudinal associations with later cognitive change patterns
- cross-population reproducibility and calibration
The stated objective is to use existing biomarker science in a standardized monitoring framework rather than create new analytes.
Cross-Lab Validation
Consistency across labs is treated as a core requirement for longitudinal monitoring. The framework describes quarterly reference sampling, proficiency testing, instrument-variance adjustment, and centralized drift monitoring for quality control.
The practical goal is to keep BAT Testing results comparable enough to support trend-based follow-up, even when collection and processing happen in different partner settings.
Long-Term Research Alignment
BAT Testing uses the same core analytes widely studied in major brain-aging and neurodegeneration research programs. That continuity allows laboratory-grade biomarker methods to be used in a broader real-world monitoring context.
Limitations and Transparency
- BAT Testing is not presented as a diagnostic test for Alzheimer’s disease or another single condition.
- Results are intended for trend tracking and should be interpreted with a licensed provider.
- Laboratory processing is described as independent and CLIA-certified.
- The framework states that BATWatch does not profit from laboratory billing or pharmaceutical sales.
Key Takeaway
BAT Testing is presented as a plasma biomarker framework grounded in established Aβ/Tau research, with emphasis on reproducible lab handling, cross-site comparability, and ongoing evidence review.
In practical terms, the value is in reliable longitudinal monitoring rather than one-time interpretation.
Research Reference
BATWatch Research Group (2025). Quantifying Brain Clearance Through BAT Testing and BATChecks. Zenodo.
https://doi.org/10.5281/zenodo.17755189